Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia

Stanic, Karmen; But-Hadzic, Jasna; Zagar, Jan; Vrankar, Martina

doi:10.2478/raon-2023-0032

Abstract

Background

Stereotactic body radiation therapy (SBRT) precisely and non-invasively delivers ablative radiation dose to tumors in early-stage lung cancer patients who are not candidates for surgery or refuse it. The aim of research was to evaluate local control, overall survival (OS), local progression free survival (LPFS), distant metastases free survival (DMFS), disease free survival (DFS) and toxicity in early-stage lung cancer patients treated with SBRT in a single tertiary cancer centre.

Patients and methods

We retrospectively evaluated medical records and radiation treatment plan parameters of 228 tumors irradiated in 206 early-stage lung cancer patients between 2016 and 2021 at the Institute of Oncology Ljubljana.

Results

After 25 months of median follow up, 68 of 206 (33%) patients died. Median OS was 46 months (CI 36–56), 1-year, 2-year and 3-year OS were 87%, 74% and 62% and 5-year OS was 31%. A total of 45 disease progressions have been identified in 41 patients. Local progress only was noticed in 5 (2%) patients, systemic progress in 32 (16%) and combined systemic and local in 4 (2%) patients. Local control rate (LCR) at 1 year was 98%, at 2 and 3 years 96% and 95% at 5 years. The 1-, 2- and 3-year LPFS were 98%, 96% and 94%, respectively and 5-year LPFS was 82%. One, 2-, 3- and 5-year DFS were 89%, 81%, 72% and 49%, respectively. Among 28 toxicities recorded only one was Grade 4 (pneumonitis), all others were Grade 1 or 2. No differences in LCR, LPFS, DFS were found in univariate analysis comparing patient, tumor, and treatment characteristics. For OS the only statistically significant difference was found in patients with more than 3 comorbidities compared to those with less comorbidities.

Conclusions

Early lung cancer treated with SBRT at single tertiary cancer centre showed that LCR, LPFS, DFS, DMFS and OS were comparable to published studies. Patients with many comorbidities had significantly worse overall survival compared to those with less comorbidities. No other significant differences by patient, tumor, or treatment characteristics were found for DMFS, LPFS, and DFS. Toxicity data confirmed that treatment was well tolerated.

References

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019; 11: 943–53. doi: 10.2147/CMAR.S187317
Open DOI Search in Google Scholar Back to article
Cancer in Slovenia 2019. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2022.
Search in Google Scholar Back to article
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1–21. doi: 10.1093/annonc/mdx222
Open DOI Search in Google Scholar Back to article
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) v 1, 2003. [cited 2022 Dec 28]. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Search in Google Scholar Back to article
Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy. Strahlenther Onkol 2014; 190: 26–33. doi: 10.1007/s00066-013-0450-y
Open DOI Search in Google Scholar Back to article
Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017; 124: 11–7. doi: 10.1016/j.radonc.2017.05.012
Open DOI Search in Google Scholar Back to article
Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body radiation therapy for operable early-stage lung cancer findings from the NRG oncology RTOG 0618 trial. JAMA Oncol 2018; 4: 1263–6. doi: 10.1001/jamaoncol.2018.1251
Open DOI Search in Google Scholar Back to article
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630–7. doi: 10.1016/S1470-2045(15)70168-3
Open DOI Search in Google Scholar Back to article
Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, et al. Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 2021; 22: 1448–57. doi: 10.1016/S1470-2045(21)00401-0
Open DOI Search in Google Scholar Back to article
JoLT-Ca sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) for lung cancer (STABLE-MATES). Clinical-TrialsGov 2015. [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02468024
Search in Google Scholar Back to article
Veterans affairs lung cancer surgery or stereotactic radiotherapy (VALOR). ClinicalTrialsGov 2016. [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02984761
Search in Google Scholar Back to article
Nyman J, Hallqvist A, Lund JA, Brustugun OT, Bergman B, Bergström P, et al. SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 2016; 121: 1–8. doi: 10.1016/j.radonc.2016.08.015
Open DOI Search in Google Scholar Back to article
Swaminath A, Parpia S, Wierzbicki M, Kundapur V, Faria SL, Okawara G, et al. LUSTRE: a phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. conventionally hypofractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2022; 114: 1061–2. doi: 10.1016/j.ijrobp.2022.09.009
Open DOI Search in Google Scholar Back to article
Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage I non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20: 494–503. doi: 10.1016/S1470-2045(18)30896-9
Open DOI Search in Google Scholar Back to article
Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37: 4078–101. doi: 10.1118/1.3438081
Open DOI Search in Google Scholar Back to article
Videtic GMM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2015; 93: 757–64. doi: 10.1016/j.ijrobp.2015.07.2260
Open DOI Search in Google Scholar Back to article
Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88: 20150036. doi: 10.1259/bjr.20150036
Open DOI Search in Google Scholar Back to article
Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, et al. Spinal cord dose tolerance to stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2021; 110: 124–36. doi: 10.1016/j.ijrobp.2019.09.038
Open DOI Search in Google Scholar Back to article
National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5. 2021. [cited 2022 Dec 29]. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
Search in Google Scholar Back to article
Peterlin P, Stanič K, Méndez I, Strojnik A. Treating lung cancer with dynamic conformal arc therapy: a dosimetric study. Radiat Oncol 2017; 12: 93. doi: 10.1186/s13014-017-0823-y
Open DOI Search in Google Scholar Back to article
Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi, G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290–6. doi: 10.1200/JCO.2008.21.5681
Open DOI Search in Google Scholar Back to article
Singh AK, Gomez-Suescun JA, Stephans KL, Bogart JA, Hermann GM, Tian L, et al. One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys 2019; 105: 752–9. doi: 10.1016/j.ijrobp.2019.08.019
Open DOI Search in Google Scholar Back to article
Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, et al. Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2019; 103: 1077–84. doi: 10.1016/j.ijrobp.2018.11.051
Open DOI Search in Google Scholar Back to article
Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol 2018; 4: 1287–8. doi: 10.1001/jamaoncol.2018.1258
Open DOI Search in Google Scholar Back to article
Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 2012; 82: 967–73. doi: 10.1016/j.ijrobp.2010.12.039
Open DOI Search in Google Scholar Back to article
Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis 2014; 6: 369–74. doi: 10.3978/j.issn.2072-1439.2013.12.03
Open DOI Search in Google Scholar Back to article
Abreu CECV, Moraes FY, Miranda FA, Siqueira GSM, Gadia R, Haddad CK, et al. Stereotactic body radiation therapy for biopsy-proven primary non-small-cell lung cancer: experience of patients with inoperable cancer at a single brazilian institution. J Glob Oncol 2018; 4: 1–8. doi: 10.1200/JGO.18.00020
Open DOI Search in Google Scholar Back to article
Doupnik NP, Hirmiz K, Hussein AA, Agapito J, Pan M. Early-stage non-small cell lung cancer stereotactic body radiation therapy outcomes in a single institution. Cureus 2022; 14: e21878. doi: 10.7759/cureus.21878
Open DOI Search in Google Scholar Back to article
Lackey A, Donington JS. Surgical management of lung cancer. Semin Intervent Radiol 2013; 30: 133–40. doi: 10.1055/s-0033-1342954
Open DOI Search in Google Scholar Back to article
Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. Survival of cancer patients, diagnosed in 1997–2016 in Slovenia. Ljubljana: Institute of Oncology Ljubljana; 2021.
Search in Google Scholar Back to article
Bitenc M, Cufer T, Kern I, Miklavcic M, Petrovic S, Groznik v, Sadikov A. Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer. Radiol Oncol 2022; 56: 346–54. doi: 10.2478/raon-2022-0030
Open DOI Search in Google Scholar Back to article
Mullins K. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: when and why is it appropriate therapy? J Adv Pract Oncol 2015; 6: 351–4. doi: 10.6004/jadpro/2015.6.4.5
Open DOI Search in Google Scholar Back to article
Haasbeek CJA, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743–7. doi: 10.1093/annonc/mds081
Open DOI Search in Google Scholar Back to article
von Reibnitz D, Shaikh F, Wu AJ, Treharne GC, Dick-Godfrey R, Foster A, et al. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). Acta Oncol 2018; 57: 1567–73. doi: 10.1080/0284186X.2018.1481292
Open DOI Search in Google Scholar Back to article
Ishikura S. Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges. Gen Thorac Cardiovasc Surg 2012; 60: 127–31. doi: 10.1007/s11748-011-0832-y
Open DOI Search in Google Scholar Back to article
Wegner RE, Ahmed N, Hasan S, Schumacher LY, Van Deusen M, Colonias A. SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions. Lung Cancer Manag 2018; 7: LMT01. doi: 10.2217/lmt-2018-0006
Open DOI Search in Google Scholar Back to article
Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis 2014; 8: 3–12. doi: 10.1177/1753465813512545
Open DOI Search in Google Scholar Back to article
Hasan S, Colonias A, Mickus T, VanDeusen M, Rodney E. Wegner RE, et al. Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: predictors from a 10 year single institution experience. Thorac Cancer 2018; 9: 699–706. doi: 10.1111/1759-7714.12635
Open DOI Search in Google Scholar Back to article
IJsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg KCA, Lebenthal A, et al. Survival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis. J Thorac Oncol 2019; 14: 583–95. doi: 10.1016/j.jtho.2018.12.035
Open DOI Search in Google Scholar Back to article
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2: S94–100. doi: 10.1097/JTO.0b013e318074de34
Open DOI Search in Google Scholar Back to article
Zhang J, Yang F, Li B, Li H, Liu J, Huang W, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011; 81: e305–16. doi: 10.1016/j.ijrobp.2011.04.034
Open DOI Search in Google Scholar Back to article
Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2015; 91: 344–50. doi: 10.1016/j.ijrobp.2014.10.002
Open DOI Search in Google Scholar Back to article
Alite F, Stang K, Balasubramanian N, Adams W, Shaikh MP, Small C, et al. Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy. Radiother Oncol 2016; 121: 9–14. doi: 10.1016/j.radonc.2016.07.026
Open DOI Search in Google Scholar Back to article
Ikawa T, Tabuchi T, Konishi K, Morimoto M, Hirata T, Kanayama N, et al. Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: a propensity score-weighted, single-center analysis. PLoS One 2021; 16: e0253203. doi: 10.1371/journal.pone.0253203
Open DOI Search in Google Scholar Back to article